Screened 2026-09-11 · the tape above runs as of 21:00 UTC · two dates, stated on purpose · verdict and workings shown in full · never trimmed
The Label · The Season, Not the Day
This name holds its markup label.
Qiagen N.V. holds its Markup at $42.50. Elevated stress, defensive posture warranted, held for 22 days.
As held on the ledger · 2026-09-11
Phase
Markup
Quantitative state
Elevated stress, defensive posture warranted, held for 22 days
Price at the screen
$42.50
Valuation
21.57 trailing · 16.27 forward price to earnings
Values screen
PASS· score 70.0
Beta
0.63
The Workings
Five Screens, Shown in Full
Full pass across all five screens. This security clears the Titan Ethical Standard: its business and its balance sheet both stay inside the lines.
Test
Figure
Limit
What it means
Status
Business activity
Permissible
Core business clean
Its core business isn't built on prohibited lines: no gambling, alcohol, tobacco, weapons, or interest-based lending.
Pass
Debt load
28.85%
Below 33%
Interest-bearing debt is just 28.9% of its assets, well under the one-third ceiling: it does not run on borrowed money.
Pass
Interest-bearing cash
4.14%
Below 33%
Cash held in interest-bearing accounts and securities is 4.1% of assets, under the one-third limit.
Pass
Receivables
19.77%
Below 49%
Money owed to the company is 19.8% of assets, under the 49% limit.
Pass
Revenue purity
3.08%
Below 5%
Only 3.1% of revenue comes from non-compliant sources, under the 5% line.
Pass
Five checks adapted from AAOIFI screening standards: business activity plus four balance-sheet ratios. All five must pass for ethical clearance. Every figure is arithmetic on public accounts, not judgement.
Fair value range in USD, drawn from the 2026-09-11 screen. The gold marker is the market price at the same screen. A 17.6% margin of safety to the base estimate.
Third-party analyst targets: 15 covering, consensus Buy. The average target sits +11% from the screen price.
Reading the gap · Both our model and the analysts see meaningful upside from here.
Price History & Projections
Where it has been, where the models see it going. History from market close data; projection points are our fair-value estimates and third-party analyst targets, dated to the 2026-09-11 screen.
Fair value and rating are our own model estimates; the Street's range reflects third-party analyst estimates. Analysis, not advice.
The Business, in Plain Words
Qiagen turns swabs into insights yet growth stalls
Every time a hospital lab processes a swab or a research team isolates genetic material, Qiagen's kits and instruments sit in the middle of the workflow. The business clears ethical screens and trades at a 20% discount to our fair value of $49.47, with a forward multiple of 15.7 times and solid 19% margins. Still, revenue is expanding just 2% a year and return on equity sits at only 12%, leaving little to excite beyond the current price of $41.15.
We pass because the low growth rate and unknown competitive position outweigh the apparent margin of safety. Analyst targets cluster around $45, which already prices in modest improvement, and nothing in the numbers suggests an acceleration that would close the gap to our higher valuation. The setup looks stable but uninspiring.
Slow expansion in diagnostics leaves the company exposed to pricing pressure from larger instrument makers and shifts in research funding. Currency moves and modest returns on capital add further drag that a single-digit growth profile does little to offset.
The risks · The things to watch: its business and earnings are exposed to Netherlands and to currency swings.
Plain-English interpretation of our own screen data. Analysis, not advice.
Where & How to Trade
QGEN trades on the NYSE (the company is based in Netherlands). As a listed security it is accessible through almost any international broker offering its home market. New to this, or investing from abroad? Our guide to accessing global markets covers brokers, currencies and the practical steps.
The framework has shifted from markup to distribution since the last review. Smart money appears to be selling into strength. Institutional holders may be rotating out. Price has moved up 4.6% since our last review. Ethical screening: PASS with passing ethical screen. The risk-adjusted return profile shows modest positive risk-adjusted returns. Our composite framework grades it C, carrying a low risk profile. Technically it is sitting below its long-term trend line with momentum reading bullish. Over the past year the shares are down 20%. Our forward projection puts the odds of a 10% gain over the next month near 13%. The street (14 analysts) rates it buy, with a mean price target of $44.
2026-08-09Markup$41.73+12.6%Entry 4
The framework reads markup. Price is trending higher with momentum. The crowd has caught on and buyers are in control. Price has moved up 12.6% since our last review. Ethical screening: PASS with passing ethical screen. The risk-adjusted return profile shows modest positive risk-adjusted returns. Our composite framework grades it C, carrying a low risk profile. Technically it is sitting below its long-term trend line with momentum reading bullish. Over the past year the shares are down 20%. Our forward projection puts the odds of a 10% gain over the next month near 13%. The street (14 analysts) rates it buy, with a mean price target of $44.
2026-07-18Markup$37.06+0.0%Entry 3
The framework reads markup. Price is trending higher with momentum. The crowd has caught on and buyers are in control. Price has moved down 0.0% since our last review. Ethical screening: PASS with passing ethical screen. The risk-adjusted return profile shows negative risk-adjusted returns. Our composite framework grades it C, carrying a low risk profile. Technically it is sitting below its long-term trend line with momentum reading bullish. Over the past year the shares are down 20%. Our forward projection puts the odds of a 10% gain over the next month near 13%. The street (14 analysts) rates it buy, with a mean price target of $44.
2026-07-03Markup$37.06+0.0%Entry 2
The framework reads markup. Price is trending higher with momentum. The crowd has caught on and buyers are in control. Price has moved down 0.0% since our last review. Ethical screening: PASS with passing ethical screen (70). The risk-adjusted return profile shows negative risk-adjusted returns.
2026-07-02Markup$37.06Entry 1
The framework reads markup. Price is trending higher with momentum. The crowd has caught on and buyers are in control. Ethical screening: PASS with passing ethical screen (70). The risk-adjusted return profile shows negative risk-adjusted returns.
Each entry above was written on its date, before the outcome. A journal you can prune is not a journal.
